Home › Acute Myeloid Leukemia › Connecticut › New Haven
Acute Myeloid Leukemia clinical trials in New Haven, CT
19 studies for Acute Myeloid Leukemia are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Yale University, New Haven
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
RecruitingPhase 1
- Yale University, New Haven
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi away
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi away
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Yale University, New Haven
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecruitingPhase 3
- Yale University, New Haven
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi away
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Yale University, New Haven
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- Yale University, New Haven
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- Smilow Cancer Hospital at Yale New Haven, New Haven
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- Yale University School of Medicine, New Haven
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RecruitingPhase 1
- Yale University, Yale Cancer Center, New Haven
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Yale New Haven Hospital, New Haven
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- Yale New Haven Hospital, New Haven
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- Yale University, New Haven
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 1
- Yale-New Haven Hospital, New Haven
Revumenib in Combination With 7+3 + Midostaurin in AML
RecruitingPhase 1
- Yale Cancer Center, New Haven
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RecruitingPhase 1
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RecruitingPhase 1/2
- Yale University, New Haven
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX86 studies
- New York City, NY51 studies
- Boston, MA45 studies
- Baldwin Park, CA40 studies
- Seattle, WA40 studies
- Columbus, OH34 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Tampa, FL29 studies
- Atlanta, GA29 studies
- Chicago, IL27 studies
- Portland, OR25 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer41 studies
- Breast Cancer37 studies
- Cancer (all types)34 studies
- Metastatic Cancer23 studies
- Lung Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Colorectal Cancer21 studies
- Prostate Cancer21 studies
- Ovarian Cancer21 studies
- Alcohol Use Disorder (AUD)17 studies
- Opioid Overdose17 studies
- Pancreatic Cancer16 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.